Hoda M Ghanem, MD
Endocrinology · Palo Alto
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- Not verified
- Not the same as out of network.
- Office
- 1
Offices
1 location · Sutter Bay Medical Foundation · 3,783 clinicians in this group
Looking this up.
Hospitals listed: Memorial Medical Center · Stanford Health Care Tri-Valley. That is not proof they admit you there this week.
Plan participation
Not verified
We could not verify current plan participation for this doctor. This does not mean they are out of network. Call Dr. Ghanem’s office at (415) 600-1020 to ask if they take your plan before you enroll.
California Medical Board record
Licence A92248 · Current
Licensed to practise in California · since 2005 · expires 2028-11-30 · Temple University School of Medicine.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Hospitals they work in
2 hospitals
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Memorial Medical CenterModesto, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of Sutter Health, which runs 27 hospitals in 2 statesPatients rate it 3 of 5 · 72% would definitely recommend itOverall rating: 3 of 5 starsBetter than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.093, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.085, Oct 2024 – Sep 2025
- Stanford Health Care Tri-ValleyPleasanton, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of Stanford Health Care, which runs 3 hospitalsPatients rate it 3 of 5 · 74% would definitely recommend itOverall rating: 5 of 5 starsBetter than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.178, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.237, Oct 2024 – Sep 2025
See every measure and the patient survey for Memorial Medical Center
Behind the star rating — Deaths: 1 better, 7 the same, 0 worse of 8 measures. Safety: 2 better, 5 the same, 0 worse of 7 measures. Readmissions: 0 better, 9 the same, 2 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.093 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.085 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.3 (0.41 to 2.2) · 2,271 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.02 (0.75 to 1.3) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 185.77 (144.66 to 226.88) · 146 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 3.2 · 105 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 6.2 · 237 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 14.1 · 194 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 12.9 · 513 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 12.4 · 640 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 9.3 · 278 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.5 · 4,882 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.22 (0.03 to 0.42) · 10,183 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.2 (0.01 to 0.38) · 10,422 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.4 (1.58 to 5.23) · 2,596 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.92 (0.45 to 3.38) · 845 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 3.1 (1.78 to 4.42) · 2,439 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 11.71 (5.69 to 17.72) · 885 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 7.28 (3.75 to 10.81) · 829 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.82 (0.4 to 3.24) · 563 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.2 (0 to 0.72) · 9,080 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.4 · 283 cases | None | Apr 2023 – Mar 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.389 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.485 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.507 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 15 · 255 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 19.9 · 849 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 19.2 · 201 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -8.4 · 584 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 26.6 · 660 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 17.9 · 895 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 4.8 (3.3 to 6.9) · 285 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 11 (8.4 to 14.3) · 285 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 4.9 · 273 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 10.7 · 108 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.4 · 341 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.9 (10.2 to 16.1) · 2,334 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1 (0.7 to 1.3) · 717 cases | No different | Jan 2024 – Dec 2024 |
What patients said (655 patients answered, 19% of those asked)
| Cleanliness | 4 |
| Nurse communication | 3 |
| Doctor communication | 3 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 3 |
| Quietness | 2 |
| Recommend hospital | 4 |
| Room was "always" clean | 72% |
| Nurses "always" communicated well | 77% |
| Doctors "always" communicated well | 76% |
| Staff "always" explained | 60% |
| Yes, staff "did" give patients this information | 88% |
| Yes, staff "did" give patients information about help after discharge | 88% |
| Doctors "always" explained things so they could understand | 71% |
| Doctors "always" listened carefully | 74% |
| Doctors "always" treated them with courtesy and respect | 83% |
| Patients who gave a rating of "9" or "10" (high) | 70% |
| Staff "always" explained new medications | 73% |
| Nurses "always" explained things so they could understand | 74% |
| Nurses "always" listened carefully | 73% |
| Nurses "always" treated them with courtesy and respect | 84% |
| "Always" quiet at night | 44% |
| "YES", patients would definitely recommend the hospital | 72% |
| Staff "always" explained possible side effects | 47% |
| Yes, staff "did" give patients information about possible symptoms | 88% |
See every measure and the patient survey for Stanford Health Care Tri-Valley
Behind the star rating — Deaths: 2 better, 6 the same, 0 worse of 8 measures. Safety: 2 better, 5 the same, 0 worse of 7 measures. Readmissions: 2 better, 7 the same, 0 worse of 9 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.178 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.237 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.79 (0 to 1.73) · 1,041 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.79 (0.5 to 1.08) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 145.81 (96.5 to 195.12) · 72 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2.9 · 55 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 8.6 · 92 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 12.5 · 96 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 9.5 · 395 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.3 · 391 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 10.1 · 162 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3 · 1,736 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.16 (0 to 0.37) · 4,425 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.22 (0.02 to 0.41) · 4,771 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.45 (1.46 to 5.44) · 1,403 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.5 (0.05 to 2.94) · 645 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 1.81 (0.38 to 3.24) · 1,279 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 8.53 (3.2 to 13.85) · 639 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.15 (1.89 to 8.41) · 648 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.61 (0.14 to 3.07) · 370 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.16 (0 to 0.83) · 4,160 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 4 · 74 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.369 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 1.112 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 13.1 · 110 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.1 · 437 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | -5.8 · 94 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -19.3 · 456 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | -0.3 · 402 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 15.8 · 358 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 6.8 (4.7 to 9.6) · 198 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 10.1 (7.5 to 13.6) · 198 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.3 · 80 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 10.9 · 46 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.3 · 92 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.4 (9.6 to 16.2) · 1,532 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1 (0.8 to 1.2) · 929 cases | No different | Jan 2024 – Dec 2024 |
What patients said (1,268 patients answered, 26% of those asked)
| Cleanliness | 3 |
| Nurse communication | 3 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 3 |
| Quietness | 2 |
| Recommend hospital | 4 |
| Room was "always" clean | 65% |
| Nurses "always" communicated well | 77% |
| Doctors "always" communicated well | 79% |
| Staff "always" explained | 58% |
| Yes, staff "did" give patients this information | 88% |
| Yes, staff "did" give patients information about help after discharge | 88% |
| Doctors "always" explained things so they could understand | 74% |
| Doctors "always" listened carefully | 78% |
| Doctors "always" treated them with courtesy and respect | 86% |
| Patients who gave a rating of "9" or "10" (high) | 70% |
| Staff "always" explained new medications | 72% |
| Nurses "always" explained things so they could understand | 73% |
| Nurses "always" listened carefully | 74% |
| Nurses "always" treated them with courtesy and respect | 84% |
| "Always" quiet at night | 42% |
| "YES", patients would definitely recommend the hospital | 74% |
| Staff "always" explained possible side effects | 44% |
| Yes, staff "did" give patients information about possible symptoms | 89% |
Original Medicare doctor bills
$95,535
Medicare paid this office $95,535 for 206 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Return visit (30+ min) | 193 | $44,547 | $115 |
| Injection, denosumab, 1 mg | 19 | $37,861 | None |
| Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | 189 | $5,293 | $15 |
| Continuous monitoring of blood sugar level in tissue fluid using sensor under skin with interpretation and report | 38 | $3,272 | $31 |
| Injection of drug or substance under skin or into muscle | 22 | $455 | $14 |
Who their Medicare patients are
206 Original Medicare patients in 2024. Average age 75 · Women 69% · Also on Medicaid 6% · Health risk score 1.10. At or below the middle of the specialty; the typical endocrinology clinician is at 1.46.
Conditions among them: High blood pressure 75% · Diabetes 50% · Chronic kidney disease 31% · Coronary heart disease 28% · Atrial fibrillation 16% · Cancer 15% · Heart failure 13% · Depression 11% · COPD 10%.
The office billed $300,693, Medicare allowed $124,216 and paid $95,535; for 3,072 services of 14 kinds; $39,651 of it was for drugs given in the office and $55,884 for care.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 206 | 3,072 | 75 | 1.10 | $300,693 | $95,535 |
| 2023 | 197 | 5,925 | 74 | 1.21 | $357,621 | $116,669 |
| 2022 | 217 | 2,398 | 74 | 1.08 | $249,684 | $78,756 |
| 2021 | 196 | 2,318 | 74 | 1.17 | $195,119 | $60,748 |
| 2020 | 263 | 6,168 | 73 | 1.29 | $300,163 | $87,154 |
| 2019 | 285 | 8,130 | 73 | 1.34 | $339,899 | $92,823 |
| 2018 | 273 | 6,489 | 73 | 1.46 | $396,308 | $99,500 |
| 2017 | 304 | 4,825 | 73 | 1.35 | $411,031 | $109,559 |
| 2016 | 308 | 3,988 | 73 | 1.40 | $391,804 | $97,743 |
| 2015 | 288 | 3,914 | 72 | 1.43 | $390,834 | $104,007 |
| 2014 | 270 | 3,051 | 72 | 1.27 | $356,884 | $92,289 |
| 2013 | 257 | 2,224 | 72 | 1.31 | $305,825 | $81,658 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 4 services
| Injection, denosumab, 1 mg | 28 | $54,241 | None |
| Return visit (30+ min) | 173 | $38,578 | $107 |
| Continuous monitoring of blood sugar level in tissue fluid using sensor under skin with interpretation and report | 36 | $3,251 | $30 |
| Injection of drug or substance under skin or into muscle | 24 | $476 | $14 |
2022: 4 services
| Return visit (30+ min) | 199 | $43,449 | $107 |
| Injection, denosumab, 1 mg | 24 | $30,611 | None |
| Continuous monitoring of blood sugar level in tissue fluid using sensor under skin with interpretation and report | 32 | $2,570 | $30 |
| Injection of drug or substance under skin or into muscle | 18 | $338 | $14 |
2021: 4 services
| Injection, denosumab, 1 mg | 23 | $30,128 | None |
| Return visit (30+ min) | 175 | $26,599 | $100 |
| Continuous monitoring of blood sugar level in tissue fluid using sensor under skin with interpretation and report | 23 | $1,292 | $28 |
| Injection of drug or substance under skin or into muscle | 24 | $404 | $13 |
2020: 6 services
| Injection, denosumab, 1 mg | 30 | $41,057 | None |
| Return visit (30+ min) | 225 | $36,372 | $90 |
| Long return visit (40+ min) | 24 | $3,244 | $116 |
| Continuous monitoring of blood sugar level in tissue fluid using sensor under skin with interpretation and report | 28 | $2,211 | $30 |
| New patient visit (45+ min) | 12 | $1,363 | $114 |
| Injection of drug or substance under skin or into muscle | 35 | $1,105 | $13 |
2019: 6 services
| Injection, denosumab, 1 mg | 31 | $44,993 | None |
| Return visit (30+ min) | 232 | $34,894 | $90 |
| Long return visit (40+ min) | 26 | $5,277 | $135 |
| New patient visit (45+ min) | 17 | $2,271 | $134 |
| Continuous monitoring of blood sugar level in tissue fluid using sensor under skin with interpretation and report | 26 | $1,740 | $30 |
| Injection of drug or substance under skin or into muscle | 33 | $1,661 | $16 |
2018: 7 services
| Injection, denosumab, 1 mg | 35 | $46,234 | None |
| Return visit (30+ min) | 228 | $34,702 | $86 |
| Long return visit (40+ min) | 37 | $7,477 | $119 |
| Injection of drug or substance under skin or into muscle | 45 | $2,914 | $20 |
| New patient visit (45+ min) | 14 | $1,353 | $97 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 14 | $1,023 | $73 |
| Injection, zoledronic acid, 1 mg | 17 | $876 | None |
2017: 7 services
| Return visit (30+ min) | 271 | $48,281 | $87 |
| Injection, denosumab, 1 mg | 33 | $43,341 | None |
| Long return visit (40+ min) | 47 | $8,050 | $112 |
| Fine needle aspiration using imaging guidance | 13 | $2,398 | $133 |
| New patient visit (45+ min) | 16 | $2,077 | $130 |
| Injection of drug or substance under skin or into muscle | 37 | $1,990 | $25 |
| Ultrasonic guidance for needle placement | 13 | $855 | $57 |
2016: 11 services
| Return visit (30+ min) | 261 | $45,909 | $85 |
| Injection, denosumab, 1 mg | 27 | $31,345 | None |
| Long return visit (40+ min) | 30 | $4,989 | $122 |
| New patient visit (45+ min) | 33 | $4,503 | $136 |
| Fine needle aspiration using imaging guidance | 18 | $3,549 | $131 |
| New patient visit (60+ min) | 12 | $2,114 | $176 |
| Injection, zoledronic acid, 1 mg | 17 | $1,417 | None |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 17 | $1,137 | $67 |
| Ultrasonic guidance for needle placement | 18 | $1,009 | $53 |
| Injection of drug or substance under skin or into muscle | 27 | $957 | $24 |
| Infusion, normal saline solution, 250 cc | 14 | $5 | None |
2015: 8 services
| Return visit (30+ min) | 248 | $51,019 | $90 |
| Injection, denosumab, 1 mg | 30 | $34,186 | None |
| New patient visit (45+ min) | 35 | $4,333 | $124 |
| Long return visit (40+ min) | 22 | $3,242 | $125 |
| Fine needle aspiration using imaging guidance | 12 | $2,839 | $135 |
| Short return visit (20+ min) | 13 | $1,122 | $59 |
| Ultrasonic guidance for needle placement | 12 | $815 | $51 |
| Injection of drug or substance under skin or into muscle | 21 | $632 | $24 |
2014: 7 services
| Return visit (30+ min) | 215 | $48,181 | $86 |
| Injection, denosumab, 1 mg | 25 | $24,385 | None |
| New patient visit (45+ min) | 41 | $5,373 | $131 |
| Fine needle aspiration using imaging guidance | 16 | $3,055 | $127 |
| Long return visit (40+ min) | 18 | $2,280 | $114 |
| Short return visit (20+ min) | 27 | $1,889 | $59 |
| Ultrasonic guidance for needle placement | 15 | $1,073 | $63 |
2013: 7 services
| Return visit (30+ min) | 198 | $36,664 | $86 |
| Injection, denosumab, 1 mg | 18 | $16,117 | None |
| New patient visit (45+ min) | 66 | $8,927 | $135 |
| Fine needle aspiration using imaging guidance | 17 | $3,515 | $130 |
| Ultrasonic guidance for needle placement | 17 | $3,430 | $202 |
| Long return visit (40+ min) | 20 | $2,790 | $127 |
| Short return visit (20+ min) | 25 | $2,393 | $60 |
Drugs they prescribed that Part D paid
$798,739
Pharmacies billed $798,739 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 1,719) in 2024. At or below the middle of the specialty; the typical endocrinology clinician is at 0%.
780 generic and 858 brand-name prescriptions · $798,739 in drug cost.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Mounjaro | 105 | $145,779 | $1,388 |
| Ozempic | 80 | $121,511 | $1,519 |
| Trulicity | 67 | $109,717 | $1,638 |
| Jardiance | 53 | $89,240 | $1,684 |
| Januvia | 39 | $59,534 | $1,527 |
See all 34 drugs
| Mounjaro | 105 | $145,779 | $1,388 |
| Ozempic | 80 | $121,511 | $1,519 |
| Trulicity | 67 | $109,717 | $1,638 |
| Jardiance | 53 | $89,240 | $1,684 |
| Januvia | 39 | $59,534 | $1,527 |
| Farxiga | 17 | $27,331 | $1,608 |
| Synthroid | 175 | $20,301 | $116 |
| Humalog Kwikpen U-100 | 14 | $10,276 | $734 |
| Lantus Solostar | 31 | $3,938 | $127 |
| Ultra-Fine Mini Pen Needle | 22 | $3,057 | $139 |
| Levoxyl | 74 | $3,006 | $41 |
| Levothyroxine | 135 | $2,930 | $22 |
| Nano 2nd Gen Pen Needle | 21 | $2,899 | $138 |
| Nateglinide | 22 | $2,489 | $113 |
| Repaglinide | 11 | $2,041 | $186 |
| Lantus | 15 | $1,933 | $129 |
| Tirosint | 12 | $1,648 | $137 |
| Risedronate | 11 | $1,258 | $114 |
| Metformin | 96 | $1,085 | $11 |
| Metformin Hcl Er | 64 | $963 | $15 |
| Rosuvastatin | 17 | $719 | $42 |
| Pioglitazone | 51 | $631 | $12 |
| Calcitriol | 18 | $616 | $34 |
| Alendronate | 54 | $590 | $11 |
| Atorvastatin | 48 | $559 | $12 |
| Glipizide Er | 20 | $453 | $23 |
| Acarbose | 14 | $404 | $29 |
| Glipizide | 36 | $393 | $11 |
| Lisinopril | 18 | $266 | $15 |
| Pravastatin | 13 | $179 | $14 |
| Spironolactone | 12 | $134 | $11 |
| Glyburide | 11 | $108 | $10 |
| Hydrochlorothiazide | 39 | $79 | $2 |
| Losartan | 11 | $66 | $6 |
Year by year
| 2024 | 1,719 | 194 | 0% (0) | 50% | $798,739 |
| 2023 | 1,766 | 189 | 0% (0) | 47% | $879,842 |
| 2022 | 1,799 | 189 | 0% (0) | 44% | $793,637 |
| 2021 | 1,736 | 201 | 0% (0) | 43% | $736,235 |
| 2020 | 2,046 | 219 | 0% (0) | 45% | $839,482 |
| 2019 | 1,855 | 211 | None | 43% | $785,384 |
| 2018 | 2,003 | 221 | 0% (0) | 43% | $701,293 |
| 2017 | 1,889 | 210 | 0% (0) | 46% | $687,632 |
| 2016 | 1,707 | 197 | 0% (0) | 45% | $470,875 |
| 2015 | 1,674 | 183 | 0% (0) | 47% | $393,069 |
| 2014 | 1,526 | 177 | 0% (0) | 51% | $404,750 |
| 2013 | 1,258 | 166 | 0% (0) | 50% | $312,649 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 36 drugs
| Trulicity | 114 | $219,806 | $1,928 |
| Jardiance | 60 | $93,048 | $1,551 |
| Mounjaro | 63 | $84,762 | $1,345 |
| Januvia | 29 | $47,486 | $1,637 |
| Ozempic | 25 | $42,024 | $1,681 |
| Farxiga | 23 | $40,871 | $1,777 |
| Humalog Kwikpen U-100 | 16 | $37,017 | $2,314 |
| Lantus Solostar | 37 | $23,644 | $639 |
| Synthroid | 183 | $23,605 | $129 |
| Rybelsus | 14 | $23,258 | $1,661 |
| Novolog Flexpen | 11 | $23,252 | $2,114 |
| Novolog | 11 | $15,588 | $1,417 |
| Levemir Flexpen | 11 | $12,319 | $1,120 |
| Levemir | 17 | $11,899 | $700 |
| Livalo | 18 | $9,752 | $542 |
| Repatha Pushtronex | 12 | $7,695 | $641 |
| Nateglinide | 22 | $5,615 | $255 |
| Levothyroxine | 141 | $3,828 | $27 |
| Levoxyl | 70 | $2,210 | $32 |
| Nano 2nd Gen Pen Needle | 15 | $2,179 | $145 |
| Acarbose | 15 | $1,995 | $133 |
| Repaglinide | 17 | $1,917 | $113 |
| Ultra-Fine Mini Pen Needle | 17 | $1,778 | $105 |
| Metformin | 102 | $1,571 | $15 |
| Pioglitazone | 60 | $1,372 | $23 |
| Rosuvastatin | 19 | $1,201 | $63 |
| Metformin Hcl Er | 72 | $1,184 | $16 |
| Spironolactone | 14 | $1,025 | $73 |
| Glipizide Er | 22 | $978 | $44 |
| Atorvastatin | 58 | $821 | $14 |
| Calcitriol | 24 | $800 | $33 |
| Alendronate | 61 | $706 | $12 |
| Glipizide | 34 | $630 | $19 |
| Pravastatin | 19 | $460 | $24 |
| Hydrochlorothiazide | 44 | $198 | $4 |
| Lisinopril | 21 | $138 | $7 |
2022: 35 drugs
| Trulicity | 149 | $256,233 | $1,720 |
| Jardiance | 48 | $83,945 | $1,749 |
| Januvia | 45 | $66,059 | $1,468 |
| Novolog Flexpen | 16 | $32,178 | $2,011 |
| Humalog Kwikpen U-100 | 14 | $31,617 | $2,258 |
| Synthroid | 197 | $23,230 | $118 |
| Lantus Solostar | 41 | $22,760 | $555 |
| Levemir Flextouch | 18 | $19,882 | $1,105 |
| Farxiga | 14 | $19,508 | $1,393 |
| Levemir | 26 | $16,536 | $636 |
| Testosterone | 17 | $13,064 | $768 |
| Novolin 70-30 | 12 | $10,465 | $872 |
| Nateglinide | 34 | $7,713 | $227 |
| Basaglar Kwikpen U-100 | 12 | $6,651 | $554 |
| Nano 2nd Gen Pen Needle | 31 | $3,926 | $127 |
| Acarbose | 26 | $3,349 | $129 |
| Ultra-Fine Mini Pen Needle | 26 | $3,259 | $125 |
| Levothyroxine | 104 | $2,289 | $22 |
| Repaglinide | 23 | $2,150 | $93 |
| Levoxyl | 50 | $2,021 | $40 |
| Pioglitazone | 75 | $1,682 | $22 |
| Metformin Hcl Er | 77 | $1,639 | $21 |
| Glipizide Er | 29 | $1,451 | $50 |
| Metformin | 112 | $1,243 | $11 |
| Atorvastatin | 60 | $1,064 | $18 |
| Calcitriol | 16 | $910 | $57 |
| Glipizide | 37 | $807 | $22 |
| Alendronate | 63 | $727 | $12 |
| Insulin | 15 | $658 | $44 |
| Spironolactone | 15 | $505 | $34 |
| Rosuvastatin | 19 | $294 | $15 |
| Pravastatin | 17 | $251 | $15 |
| Glyburide | 11 | $224 | $20 |
| Lisinopril | 20 | $190 | $9 |
| Hydrochlorothiazide | 33 | $122 | $4 |
2021: 37 drugs
| Trulicity | 107 | $195,840 | $1,830 |
| Januvia | 56 | $80,354 | $1,435 |
| Jardiance | 40 | $63,699 | $1,592 |
| Humalog Kwikpen U-100 | 28 | $51,473 | $1,838 |
| Victoza 3-Pak | 20 | $36,936 | $1,847 |
| Lantus Solostar | 36 | $26,814 | $745 |
| Humalog | 15 | $25,688 | $1,713 |
| Levemir Flextouch | 22 | $24,166 | $1,098 |
| Synthroid | 199 | $22,741 | $114 |
| Levemir | 29 | $17,270 | $596 |
| Colesevelam | 17 | $12,789 | $752 |
| Novolog | 13 | $10,964 | $843 |
| Nateglinide | 33 | $8,722 | $264 |
| Basaglar Kwikpen U-100 | 13 | $5,863 | $451 |
| Acarbose | 31 | $4,652 | $150 |
| Ultra-Fine Mini Pen Needle | 35 | $3,974 | $114 |
| Testosterone | 16 | $3,749 | $234 |
| Repaglinide | 17 | $2,571 | $151 |
| Levothyroxine | 92 | $2,344 | $25 |
| Levoxyl | 43 | $2,205 | $51 |
| Glipizide Er | 40 | $2,126 | $53 |
| Nano 2nd Gen Pen Needle | 19 | $1,766 | $93 |
| Pioglitazone | 58 | $1,249 | $22 |
| Metformin Hcl Er | 58 | $1,040 | $18 |
| Atorvastatin | 54 | $1,004 | $19 |
| Metformin | 108 | $1,002 | $9 |
| Insulin | 19 | $916 | $48 |
| Rosuvastatin | 20 | $855 | $43 |
| Fenofibrate | 12 | $836 | $70 |
| Glipizide | 35 | $757 | $22 |
| Alendronate | 43 | $575 | $13 |
| Calcitriol | 14 | $544 | $39 |
| Pravastatin | 27 | $520 | $19 |
| Spironolactone | 17 | $361 | $21 |
| Lisinopril | 25 | $306 | $12 |
| Losartan | 13 | $297 | $23 |
| Hydrochlorothiazide | 40 | $250 | $6 |
2020: 46 drugs
| Trulicity | 94 | $155,390 | $1,653 |
| Januvia | 72 | $90,605 | $1,258 |
| Victoza 3-Pak | 51 | $77,025 | $1,510 |
| Jardiance | 35 | $42,497 | $1,214 |
| Humalog | 21 | $38,443 | $1,831 |
| Testosterone | 20 | $32,388 | $1,619 |
| Novolog | 24 | $22,730 | $947 |
| Levemir Flextouch | 20 | $21,174 | $1,059 |
| Humalog Kwikpen U-100 | 15 | $20,828 | $1,389 |
| Synthroid | 220 | $20,140 | $92 |
| Janumet | 13 | $18,588 | $1,430 |
| Lantus Solostar | 37 | $17,840 | $482 |
| Levemir | 25 | $16,581 | $663 |
| Novolog Flexpen | 16 | $16,542 | $1,034 |
| Lantus | 15 | $12,417 | $828 |
| Janumet Xr | 14 | $10,253 | $732 |
| Nateglinide | 37 | $8,458 | $229 |
| Novolin R | 16 | $7,569 | $473 |
| Basaglar Kwikpen U-100 | 12 | $5,163 | $430 |
| Ultra-Fine Mini Pen Needle | 40 | $4,386 | $110 |
| Acarbose | 33 | $3,680 | $112 |
| Levothyroxine | 127 | $3,478 | $27 |
| Repaglinide | 18 | $2,549 | $142 |
| Glipizide Er | 50 | $2,304 | $46 |
| Levoxyl | 50 | $2,188 | $44 |
| Metformin Hcl Er | 84 | $2,139 | $25 |
| Pioglitazone | 63 | $1,955 | $31 |
| Insulin | 31 | $1,781 | $57 |
| Ultra-Fine Nano Pen Needle | 15 | $1,735 | $116 |
| Rosuvastatin | 21 | $1,653 | $79 |
| Atorvastatin | 58 | $1,521 | $26 |
| Metformin | 117 | $1,275 | $11 |
| Spironolactone | 14 | $1,138 | $81 |
| Risedronate | 17 | $895 | $53 |
| Glipizide | 41 | $815 | $20 |
| Fenofibrate | 12 | $774 | $65 |
| Pravastatin | 33 | $704 | $21 |
| Insulin | 14 | $653 | $47 |
| Calcitriol | 13 | $595 | $46 |
| Alendronate | 45 | $574 | $13 |
| Liothyronine | 16 | $535 | $33 |
| Lisinopril | 33 | $456 | $14 |
| Losartan | 13 | $274 | $21 |
| Hydrochlorothiazide | 44 | $137 | $3 |
| Glimepiride | 12 | $127 | $11 |
| Amlodipine Besylate | 17 | $110 | $6 |
2019: 44 drugs
| Januvia | 67 | $85,565 | $1,277 |
| Trulicity | 51 | $70,590 | $1,384 |
| Forteo | 13 | $68,546 | $5,273 |
| Victoza 3-Pak | 35 | $57,593 | $1,646 |
| Humalog Kwikpen U-100 | 15 | $31,533 | $2,102 |
| Humalog | 29 | $30,326 | $1,046 |
| Novolog | 19 | $27,665 | $1,456 |
| Levemir Flextouch | 23 | $26,687 | $1,160 |
| Novolog Flexpen | 17 | $18,470 | $1,086 |
| Humulin 70/30 Kwikpen | 14 | $18,438 | $1,317 |
| Lantus | 18 | $17,361 | $964 |
| Levemir | 28 | $15,510 | $554 |
| Jardiance | 11 | $15,387 | $1,399 |
| Synthroid | 160 | $14,078 | $88 |
| Lantus Solostar | 32 | $13,661 | $427 |
| Invokana | 13 | $7,334 | $564 |
| Novolin R | 24 | $7,321 | $305 |
| Nateglinide | 35 | $6,437 | $184 |
| Acarbose | 34 | $5,312 | $156 |
| Novolin 70-30 | 12 | $3,818 | $318 |
| Ultra-Fine Mini Pen Needle | 39 | $3,724 | $95 |
| Levothyroxine | 110 | $2,894 | $26 |
| Levoxyl | 52 | $2,700 | $52 |
| Pioglitazone | 62 | $2,263 | $37 |
| Glipizide Er | 39 | $1,970 | $51 |
| Glipizide | 63 | $1,919 | $30 |
| Repaglinide | 17 | $1,864 | $110 |
| Insulin | 29 | $1,718 | $59 |
| Metformin | 121 | $1,626 | $13 |
| Atorvastatin | 64 | $1,626 | $25 |
| Risedronate | 22 | $1,572 | $71 |
| Rosuvastatin | 22 | $1,362 | $62 |
| Ultra-Fine Nano Pen Needle | 11 | $1,218 | $111 |
| Spironolactone | 12 | $987 | $82 |
| Fenofibrate | 13 | $978 | $75 |
| Metformin Hcl Er | 56 | $976 | $17 |
| Pravastatin | 35 | $901 | $26 |
| Insulin | 22 | $738 | $34 |
| Alendronate | 44 | $683 | $16 |
| Liothyronine | 17 | $662 | $39 |
| Glimepiride | 11 | $376 | $34 |
| Lisinopril | 30 | $312 | $10 |
| Amlodipine Besylate | 30 | $260 | $9 |
| Hydrochlorothiazide | 45 | $205 | $5 |
2018: 49 drugs
| Januvia | 65 | $72,845 | $1,121 |
| Forteo | 14 | $66,194 | $4,728 |
| Trulicity | 28 | $47,741 | $1,705 |
| Novolog | 20 | $44,438 | $2,222 |
| Novolog Flexpen | 24 | $40,666 | $1,694 |
| Androgel | 11 | $38,178 | $3,471 |
| Victoza 3-Pak | 25 | $37,548 | $1,502 |
| Humalog Kwikpen U-100 | 14 | $32,781 | $2,342 |
| Humalog | 47 | $29,301 | $623 |
| Levemir | 37 | $21,235 | $574 |
| Levemir Flextouch | 18 | $19,036 | $1,058 |
| Humulin 70/30 Kwikpen | 15 | $16,871 | $1,125 |
| Synthroid | 183 | $15,753 | $86 |
| Novolog Mix 70-30 Flexpen | 11 | $15,429 | $1,403 |
| Lantus | 22 | $14,240 | $647 |
| Janumet | 13 | $13,501 | $1,039 |
| Invokana | 20 | $12,311 | $616 |
| Lantus Solostar | 29 | $11,612 | $400 |
| Nateglinide | 56 | $9,397 | $168 |
| Tradjenta | 16 | $9,043 | $565 |
| Novolin 70-30 | 12 | $5,426 | $452 |
| Acarbose | 37 | $4,937 | $133 |
| Novolin R | 17 | $4,537 | $267 |
| Risedronate | 24 | $3,816 | $159 |
| Levothyroxine | 125 | $3,588 | $29 |
| Ultra-Fine Mini Pen Needle | 38 | $3,566 | $94 |
| Levoxyl | 59 | $2,520 | $43 |
| Glipizide | 81 | $2,188 | $27 |
| Pioglitazone | 82 | $2,130 | $26 |
| Fenofibrate | 19 | $1,852 | $97 |
| Glipizide Er | 42 | $1,773 | $42 |
| Metformin | 115 | $1,680 | $15 |
| Insulin | 27 | $1,677 | $62 |
| Atorvastatin | 72 | $1,504 | $21 |
| Ultra-Fine Nano Pen Needle | 11 | $1,494 | $136 |
| Rosuvastatin | 34 | $1,489 | $44 |
| Pravastatin | 35 | $1,059 | $30 |
| Repaglinide | 14 | $933 | $67 |
| Liothyronine | 21 | $854 | $41 |
| Calcitriol | 13 | $819 | $63 |
| Spironolactone | 15 | $737 | $49 |
| Metformin Hcl Er | 46 | $674 | $15 |
| Alendronate | 50 | $669 | $13 |
| Insulin | 25 | $571 | $23 |
| Ramipril | 12 | $316 | $26 |
| Hydrochlorothiazide | 55 | $293 | $5 |
| Amlodipine Besylate | 24 | $209 | $9 |
| Lisinopril | 21 | $194 | $9 |
| Losartan | 14 | $165 | $12 |
2017: 46 drugs
| Januvia | 75 | $74,925 | $999 |
| Androgel | 21 | $53,495 | $2,547 |
| Humalog Kwikpen U-100 | 25 | $52,587 | $2,103 |
| Victoza 3-Pak | 25 | $41,293 | $1,652 |
| Novolog | 26 | $38,411 | $1,477 |
| Novolog Flexpen | 30 | $34,279 | $1,143 |
| Lantus | 42 | $22,355 | $532 |
| Humalog | 34 | $21,043 | $619 |
| Lantus Solostar | 43 | $20,482 | $476 |
| Trulicity | 16 | $19,824 | $1,239 |
| Humulin 70/30 Kwikpen | 17 | $18,985 | $1,117 |
| Invokana | 33 | $18,714 | $567 |
| Novolog Mix 70-30 Flexpen | 15 | $14,308 | $954 |
| Synthroid | 172 | $14,119 | $82 |
| Levemir Flextouch | 18 | $12,683 | $705 |
| Nateglinide | 36 | $6,950 | $193 |
| Metformin Hcl Er | 48 | $4,286 | $89 |
| Levothyroxine | 119 | $3,854 | $32 |
| Acarbose | 25 | $3,690 | $148 |
| Novolin N | 12 | $3,078 | $256 |
| Levoxyl | 60 | $2,711 | $45 |
| Pioglitazone | 76 | $2,681 | $35 |
| Ultra-Fine Mini Pen Needle | 32 | $2,656 | $83 |
| Glipizide Er | 28 | $1,848 | $66 |
| Rosuvastatin | 27 | $1,664 | $62 |
| Pravastatin | 44 | $1,638 | $37 |
| Repaglinide | 18 | $1,575 | $88 |
| Atorvastatin | 70 | $1,550 | $22 |
| Insulin | 27 | $1,481 | $55 |
| Glipizide | 69 | $1,437 | $21 |
| Fenofibrate | 20 | $1,407 | $70 |
| Metformin | 105 | $1,357 | $13 |
| Insulin | 33 | $1,090 | $33 |
| Calcitriol | 14 | $1,025 | $73 |
| Risedronate | 11 | $906 | $82 |
| Glimepiride | 13 | $727 | $56 |
| Glipizide Xl | 14 | $724 | $52 |
| Insulin | 15 | $716 | $48 |
| Liothyronine | 17 | $621 | $37 |
| Ultra-Fine Nano Pen Needle | 11 | $507 | $46 |
| Alendronate | 40 | $343 | $9 |
| Lisinopril | 28 | $255 | $9 |
| Hydrochlorothiazide | 39 | $205 | $5 |
| Prednisone | 11 | $154 | $14 |
| Losartan | 12 | $148 | $12 |
| Amlodipine Besylate | 20 | $139 | $7 |
2016: 37 drugs
| Januvia | 54 | $48,630 | $901 |
| Humalog Kwikpen U-100 | 32 | $46,764 | $1,461 |
| Novolog Flexpen | 32 | $39,059 | $1,221 |
| Victoza 3-Pak | 25 | $32,610 | $1,304 |
| Lantus | 45 | $28,497 | $633 |
| Humulin 70/30 Kwikpen | 17 | $18,905 | $1,112 |
| Lantus Solostar | 28 | $18,641 | $666 |
| Synthroid | 195 | $15,005 | $77 |
| Levemir Flextouch | 19 | $11,981 | $631 |
| Humalog | 25 | $10,163 | $407 |
| Invokana | 18 | $8,429 | $468 |
| Nateglinide | 35 | $4,298 | $123 |
| Acarbose | 36 | $4,292 | $119 |
| Bd Ultra-Fine Pen Needle | 53 | $3,791 | $72 |
| Levothyroxine | 84 | $2,466 | $29 |
| Levoxyl | 53 | $2,176 | $41 |
| Rosuvastatin | 14 | $1,893 | $135 |
| Metformin Hcl Er | 40 | $1,762 | $44 |
| Metformin | 102 | $1,421 | $14 |
| Atorvastatin | 61 | $1,374 | $23 |
| Glipizide | 71 | $1,368 | $19 |
| Glipizide Er | 35 | $1,356 | $39 |
| Pioglitazone | 60 | $1,343 | $22 |
| Pravastatin | 37 | $1,262 | $34 |
| Insulin | 14 | $944 | $67 |
| Calcitriol | 14 | $941 | $67 |
| Glipizide Xl | 20 | $866 | $43 |
| Insulin | 30 | $865 | $29 |
| Fenofibrate | 12 | $829 | $69 |
| Glimepiride | 19 | $729 | $38 |
| Repaglinide | 12 | $720 | $60 |
| Ramipril | 15 | $611 | $41 |
| Alendronate | 31 | $326 | $11 |
| Amlodipine Besylate | 28 | $287 | $10 |
| Lisinopril | 32 | $244 | $8 |
| Losartan | 14 | $224 | $16 |
| Hydrochlorothiazide | 37 | $149 | $4 |
2015: 37 drugs
| Novolog Flexpen | 41 | $54,051 | $1,318 |
| Januvia | 61 | $46,694 | $765 |
| Lantus | 63 | $39,593 | $628 |
| Novolog | 68 | $36,313 | $534 |
| Victoza 3-Pak | 25 | $30,581 | $1,223 |
| Lantus Solostar | 27 | $16,181 | $599 |
| Synthroid | 221 | $14,252 | $64 |
| Humulin 70/30 Kwikpen | 11 | $11,487 | $1,044 |
| Crestor | 20 | $10,756 | $538 |
| Invokana | 14 | $6,883 | $492 |
| Pioglitazone | 44 | $4,920 | $112 |
| Novolin 70-30 | 11 | $4,736 | $431 |
| Nateglinide | 21 | $3,883 | $185 |
| Bd Ultra-Fine Pen Needle | 54 | $3,747 | $69 |
| Levothyroxine | 88 | $2,500 | $28 |
| Acarbose | 21 | $2,046 | $97 |
| Colestipol | 12 | $1,962 | $163 |
| Metformin Hcl Er | 24 | $1,928 | $80 |
| Atorvastatin | 79 | $1,893 | $24 |
| Insulin | 26 | $1,253 | $48 |
| Metformin | 112 | $1,244 | $11 |
| Pravastatin | 34 | $1,209 | $36 |
| Glipizide | 70 | $994 | $14 |
| Levoxyl | 26 | $733 | $28 |
| Ramipril | 12 | $729 | $61 |
| Glipizide Er | 17 | $686 | $40 |
| Glipizide Xl | 16 | $604 | $38 |
| Novofine 32 | 11 | $577 | $52 |
| Ibandronate | 14 | $439 | $31 |
| Insulin | 17 | $408 | $24 |
| Glimepiride | 18 | $397 | $22 |
| Alendronate | 35 | $320 | $9 |
| Hydrochlorothiazide | 48 | $270 | $6 |
| Losartan | 16 | $269 | $17 |
| Amlodipine Besylate | 23 | $243 | $11 |
| Lisinopril | 30 | $177 | $6 |
| Simvastatin | 17 | $96 | $6 |
2014: 38 drugs
| Januvia | 60 | $42,642 | $711 |
| Novolog Flexpen | 40 | $34,277 | $857 |
| Lantus | 56 | $33,620 | $600 |
| Humulin R | 17 | $33,193 | $1,953 |
| Victoza 3-Pak | 25 | $27,517 | $1,101 |
| Humalog | 22 | $25,499 | $1,159 |
| Novolog | 56 | $20,688 | $369 |
| Forteo | 11 | $18,069 | $1,643 |
| Lantus Solostar | 31 | $15,188 | $490 |
| Crestor | 37 | $13,474 | $364 |
| Humulin N | 12 | $13,373 | $1,114 |
| Apidra Solostar | 15 | $11,041 | $736 |
| Synthroid | 191 | $10,821 | $57 |
| Humulin 70/30 Kwikpen | 13 | $10,251 | $789 |
| Humulin 70-30 | 15 | $5,970 | $398 |
| Invokana | 15 | $4,562 | $304 |
| Niacin Er | 15 | $4,458 | $297 |
| Pioglitazone | 30 | $4,263 | $142 |
| Bd Ultra-Fine Pen Needle | 70 | $3,890 | $56 |
| Nateglinide | 20 | $3,707 | $185 |
| Acarbose | 21 | $2,838 | $135 |
| Insulin | 42 | $1,849 | $44 |
| Colestipol | 11 | $1,734 | $158 |
| Metformin | 85 | $1,672 | $20 |
| Glipizide | 88 | $1,564 | $18 |
| Levothyroxine | 54 | $1,483 | $27 |
| Atorvastatin | 41 | $1,235 | $30 |
| Insulin | 28 | $937 | $33 |
| Pravastatin | 35 | $872 | $25 |
| Metformin Hcl Er | 12 | $862 | $72 |
| Hydrocortisone | 12 | $697 | $58 |
| Novofine 32 | 11 | $656 | $60 |
| Glipizide Er | 13 | $435 | $33 |
| Glipizide Xl | 11 | $295 | $27 |
| Alendronate | 30 | $292 | $10 |
| Lisinopril | 31 | $245 | $8 |
| Hydrochlorothiazide | 26 | $225 | $9 |
| Simvastatin | 11 | $108 | $10 |
2013: 33 drugs
| Novolog | 58 | $35,827 | $618 |
| Lantus | 80 | $34,049 | $426 |
| Januvia | 44 | $26,346 | $599 |
| Forteo | 20 | $25,786 | $1,289 |
| Humalog | 36 | $20,504 | $570 |
| Novolog Flexpen | 23 | $13,474 | $586 |
| Crestor | 40 | $11,838 | $296 |
| Victoza 3-Pak | 11 | $11,571 | $1,052 |
| Apidra Solostar | 12 | $9,298 | $775 |
| Levemir Flexpen | 19 | $8,520 | $448 |
| Lantus Solostar | 21 | $6,931 | $330 |
| Nateglinide | 27 | $5,711 | $212 |
| Synthroid | 95 | $5,487 | $58 |
| Pioglitazone | 15 | $5,198 | $347 |
| Niaspan | 14 | $4,984 | $356 |
| Novolin 70-30 | 16 | $3,482 | $218 |
| Bd Ultra-Fine Pen Needle | 59 | $2,672 | $45 |
| Insulin | 47 | $1,751 | $37 |
| Acarbose | 11 | $1,679 | $153 |
| Fenofibrate | 16 | $1,535 | $96 |
| Metformin | 55 | $1,094 | $20 |
| Insulin | 21 | $995 | $47 |
| Pravastatin | 43 | $980 | $23 |
| Glipizide | 51 | $917 | $18 |
| Novolin R | 11 | $822 | $75 |
| Insulin | 22 | $663 | $30 |
| Levothyroxine | 39 | $662 | $17 |
| Novolin N | 12 | $635 | $53 |
| Glipizide Er | 14 | $523 | $37 |
| Alendronate | 35 | $470 | $13 |
| Hydrocortisone | 11 | $305 | $28 |
| Lisinopril | 26 | $233 | $9 |
| Hydrochlorothiazide | 29 | $163 | $6 |
Money from drug and device companies
$18 in 2020
A payment is not proof that care is biased.
| Amgen | Evenity | $18 | 1 payment
|
See the published payment
| Amgen | Meals · 2020-02-04 | Evenity | $18 |
Professional record
- NPI
- 1114131166
- Licence
- CA A92248California A92248: Current · expires 2028-11-30
- Trained
- Temple University School of Medicine, 2004
- Video visits
- Lists video visits
- Gender
- Female
More record details
- Sole proprietor
- No
- Taxonomy
- Federal specialty code 207RE0101X (207RE0101X); Internal medicine (207R00000X)
- Mailing address
- 325 Distel Cir, Los Altos, CA, 94022
- NPI first listed
- 2007-05-09
- NPI last updated
- 2020-10-09
- NPI record certified
- 2020-10-09
This is when the NPI record was last certified, not a medical board exam.
Extra NPI addresses: 3200 Kearney Street, Fremont, CA, 94588